首頁 > 市場調查報告書 > 製藥

生物製劑

全球細胞免疫治療市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

市場調查報告書

商品編碼

1342894

全球細胞免疫治療市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

Global Cellular Immunotherapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年08月01日 | 出版商:

Value Market Research | 英文 171 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到2030年，全球細胞免疫治療市場的市場規模將從2022年的93.5億美元達到近673.4億美元，2023-2030年研究期間的年複合成長率為24.53%。

細胞免疫療法被定義為一種創新的癌症治療方法，利用我們的免疫系統細胞來消除癌症。細胞免疫治療方法涉及直接分離免疫細胞並簡單地增加其數量，而其他方法則涉及通過基因治療對免疫細胞進行基因改造，以增強其破壞腫瘤的能力。細胞免疫療法比舊療法受到廣泛青睞，因為它提供長期的癌症保護，副作用較小，並且已成功治療不同的癌症，如乳腺癌、前列腺癌、黑色素瘤、肺癌等。細胞免疫療法是通過將免疫細胞引導至癌症特異性靶標、激活免疫系統在靶標處聚集並觸發能夠破壞骨髓瘤細胞的免疫反應來進行的。

市場動態：

細胞免疫治療市場的強勁成長是由多種因素推動的，例如免疫療法相對於傳統療法的接受度不斷提高、生物學名藥的不斷出現、對單克隆抗體(mAb) 的需求不斷增加以及不斷成長的人口中癌症患病率的上升。由於選擇細胞免疫療法作為替代治療選擇的患者生存率提高，細胞免疫療法的市場將會成長。推動細胞免疫療法市場成長的其他因素包括醫療保健支出的增加、研發活動的增加、醫療保險的便捷性以及癌症治療方法技術進步的激增。

該研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球細胞免疫治療市場的每個細分市場進行了包容性評估。細胞免疫治療行業的成長和趨勢為這項研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲細胞免疫治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。細胞免疫治療市場的主要參與者包括百時美施貴寶公司、諾華公司、吉利德科學公司（Kite Pharma）、羅氏公司、默克公司、葛蘭素史克公司、阿斯利康公司、輝瑞公司、強生公司。 Johnson、Celyad、Adicet Bio Inc.、Dendreon Pharmaceuticals LLC。本節包含競爭格局的整體視圖，包括各種戰略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望銷售分析
簡介銷售分析
北美銷售分析
- 概述、歷史和預測銷售分析
- 北美按細分市場銷售分析
- 北美按國家/地區銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概述、歷史和預測銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家/地區銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概述、歷史和預測銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概述、歷史和預測銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家/地區銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概述、歷史和預測銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 10 章：細胞免疫治療公司的競爭格局

細胞免疫治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 11 章：公司簡介

十大公司股票分析
市場集中度
Bristol-Myers Squibb Company

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Gilead Sciences Inc. (Kite Pharma)

公司簡介
公司收入
產品
最近的發展

F. Hoffmann-La Roche Ltd

公司簡介
公司收入
產品
最近的發展

Merck KGaA

公司簡介
公司收入
產品
最近的發展

GlaxoSmithKline plc.

公司簡介
公司收入
產品
最近的發展

AstraZeneca

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Johnson & Johnson

公司簡介
公司收入
產品
最近的發展

Celyad

公司簡介
公司收入
產品
最近的發展

Adicet Bio Inc.

公司簡介
公司收入
產品
最近的發展

Dendreon Pharmaceuticals LLC

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私營公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR11219156

The global demand for Cellular Immunotherapy Market is presumed to reach the market size of nearly USD 67.34 BN by 2030 from USD 9.35 BN in 2022 with a CAGR of 24.53% under the study period 2023 - 2030.

Cellular immunotherapy is defined as an innovative cancer treatment approach that uses the cells of our immune system to eliminate cancer. Cellular immunotherapy approaches involve directly isolating immune cells & simply multiplying their numbers, whereas others involve genetically engineered immune cells through gene therapy to enhance their tumor-destroying capabilities. Cellular immunotherapy is widely preferred over old treatment because it provides long-term cancer protection, has lesser side effects, and has been successful in treating different cancers such as breast cancer, prostate cancer, melanoma, lung cancer, and many others. Cellular immunotherapy is performed by directing the immune cells toward cancer-specific targets, activating the immune system to assemble at the target, and triggering an immune response capable of destroying myeloma cells.

MARKET DYNAMICS:

This robust growth of the cellular immunotherapy market is driven by several factors such as increasing acceptance of immunotherapy over conventional therapies, growing emergence of biosimilars, increasing demand for monoclonal antibodies (mAbs), and rising prevalence of cancer among a growing population. The market for cellular immunotherapy will increase due to the increased survival rate of patients who choose it as an alternative treatment option. Other factors propelling the market growth of cellular immunotherapy are an increase in healthcare spending, Increasing R&D activities, easy access to medical insurance, and a surge in technological advancements in cancer treatment methods.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cellular immunotherapy. The growth and trends of cellular immunotherapy industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the cellular immunotherapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapy Type

Car T Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
TIL Therapy
Others

By Indication

B-Cell Malignancies
Prostate Cancer
Liver Cancer
Renal Cell Carcinoma
Others

By End-Use

Hospitals
Cancer Institutes
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Cellular Immunotherapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cellular immunotherapy market include Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc. (Kite Pharma), F. Hoffmann-La Roche Ltd, Merck KGaA, GlaxoSmithKline plc., AstraZeneca, Pfizer Inc., Johnson & Johnson, Celyad, Adicet Bio Inc., Dendreon Pharmaceuticals LLC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . CELLULAR IMMUNOTHERAPY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Therapy Type
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By End-use
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET ANALYSIS BY THERAPY TYPE

6.1 Overview by Therapy Type
6.2 Historical and Forecast Data
6.3 Analysis by Therapy Type
6.4 CAR T Cell Therapy Historic and Forecast Sales by Regions
6.5 Dendritic Cell Therapy Historic and Forecast Sales by Regions
6.6 NK Cell Therapy Historic and Forecast Sales by Regions
6.7 TIL Therapy Historic and Forecast Sales by Regions
6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET ANALYSIS BY INDICATION

7.1 Overview by Indication
7.2 Historical and Forecast Data
7.3 Analysis by Indication
7.4 B-cell Malignancies Historic and Forecast Sales by Regions
7.5 Prostate Cancer Historic and Forecast Sales by Regions
7.6 Liver Cancer Historic and Forecast Sales by Regions
7.7 Renal Cell Carcinoma Historic and Forecast Sales by Regions
7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET SALES ANALYSIS BY END-USE

8.1 Overview by End-use
8.2 Historical and Forecast Data
8.3 Analysis by End-use
8.4 Hospitals Historic and Forecast Sales by Regions
8.5 Cancer Institutes Historic and Forecast Sales by Regions
8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CELLULAR IMMUNOTHERAPY COMPANIES

10.1. Cellular Immunotherapy Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF CELLULAR IMMUNOTHERAPY INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Bristol-Myers Squibb Company
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. Novartis AG
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Gilead Sciences Inc. (Kite Pharma)
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. F. Hoffmann-La Roche Ltd
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Merck KGaA
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. GlaxoSmithKline plc.
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. AstraZeneca
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Pfizer Inc.
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Johnson & Johnson
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Celyad
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments
11.13. Adicet Bio Inc.
- 11.13.1. Company Overview
- 11.13.2. Company Revenue
- 11.13.3. Products
- 11.13.4. Recent Developments
11.14. Dendreon Pharmaceuticals LLC
- 11.14.1. Company Overview
- 11.14.2. Company Revenue
- 11.14.3. Products
- 11.14.4. Recent Developments